The release of prostaglandins and XXXX into the @entity2670 of @entity840 during the oestrous cycle and following @entity2931 treatment.

@entity2931 @entity1421 @entity840 @entity1871 @entity3774 @entity2670
1. Blood was collected from the utero-ovarian vein of @entity840 on days 3, 9, 10, 11, 12, 13, 14 and 15 of the oestrous cycle, and from animals injected with @entity2931 over days 4-6 and used on day 7. The content of @entity3774 and E(2) was determined by bio-assay and gas chromatography-mass spectrometry, and of @entity1871 by competitive protein binding assay.2. The concentration of @entity3774 on day 3 was 14.1 ng/ml.; it fell below detectable limits on day 7, but after day 11 the concentration rose to between 15.7-17.2 ng/ml. A value of 60.7 ng/ml. was recorded on day 15.3. The release of @entity3774 was increased in animals pre-treated with @entity2931 but was below threshold levels in similarly treated hysterectomized females.4. @entity1421 was not detectable in blood collected on days 3, 9, 10, 11 and 12. From a threshold value of 1.1 ng/ml. on day 13, the concentration rose to 5.4 ng/ml. on day 14 and to 54.9 ng/ml. on day 15.5. The @entity1871 concentration rose from 66 ng/ml. on day 3 to values of 80-180 ng/ml. between days 9-14. It fell to 45 ng/ml. between days 14 and 15.6. This work establishes that @entity3774 is released into the @entity2670 , and that its concentration fluctuates in the course of the oestrous cycle and can be related to changes in luteal function.
